Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience

BACKGROUND: Randomized studies of neoadjuvant (NA) trastuzumab and pertuzumab combined with chemotherapy for HER2-positive breast cancers (BC) have reported pathological complete response (pCR) rates of 39 to 61%. This study aimed to determine the real-world efficacy and toxicity of NA trastuzumab a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Benjamin James, Bhojwani, Ajay Ashok, Wong, Helen, Law, Andrea, Flint, Helen, Ahmed, Eliyaz, Innes, Helen, Cliff, Joanne, Malik, Zaf, O'Hagan, Julie Elizabeth, Hall, Allison, Sripadam, Rajaram, Tolan, Shaun, Ali, Zulfiqar, Hart, Clare, Errington, Douglas, Alam, Farida, Giuliani, Rosa, Mehta, Shaveta, Khanduri, Sheena, Thorp, Nicky, Jackson, Richard, Cicconi, Silvia, Palmieri, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262537/
https://www.ncbi.nlm.nih.gov/pubmed/35833190
http://dx.doi.org/10.1155/2022/7146172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262537/
https://www.ncbi.nlm.nih.gov/pubmed/35833190
http://dx.doi.org/10.1155/2022/7146172

Ejemplares similares